{"id":687272,"date":"2024-02-08T16:34:02","date_gmt":"2024-02-08T16:34:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=687272"},"modified":"2024-02-08T16:34:02","modified_gmt":"2024-02-08T16:34:02","slug":"al-amyloidosis-market-to-register-incremental-growth-during-the-forecast-period-20232032-delveinsight-caelum-biosciences-nexcella-haemalogix-prothena-zentalis-pharmaceuticals-sorrento-ther","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/al-amyloidosis-market-to-register-incremental-growth-during-the-forecast-period-20232032-delveinsight-caelum-biosciences-nexcella-haemalogix-prothena-zentalis-pharmaceuticals-sorrento-ther_687272.html","title":{"rendered":"AL Amyloidosis Market to Register Incremental Growth During the Forecast Period (2023-2032) – DelveInsight | Caelum Biosciences, Nexcella, Haemalogix, Prothena, Zentalis Pharmaceuticals, Sorrento Ther"},"content":{"rendered":"
\n
\"AL<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The landscape of AL Amyloidosis, a rare disease characterized by the accumulation of abnormal proteins in tissues and organs, is undergoing notable transformation. Recent advancements in understanding the pathophysiology of the disease have led to the development of targeted therapies aimed at disrupting the production of amyloidogenic proteins.<\/div>\n

Additionally, there is a growing focus on early diagnosis and multidisciplinary care approaches to improve patient outcomes and quality of life. With ongoing research efforts and collaborations between academia, industry, and patient advocacy groups, there is optimism for further breakthroughs in the management of AL Amyloidosis.<\/em><\/p>\n

DelveInsight’s “AL Amyloidosis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the AL Amyloidosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging AL Amyloidosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current AL Amyloidosis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

AL Amyloidosis: An Overview<\/strong><\/p>\n

Amyloidosis is a rare disease resulting from abnormal protein deposits, called amyloid, in various tissues of the body. Depending on the structure of the particular amyloid, the protein can accumulate in an isolated tissue or be widespread, affecting numerous organs and tissues. There are over 30 different amyloid proteins. Each amyloid protein is arranged in a structure called fibril-low molecular weight proteins derived from precursor proteins. Fibrils of amyloid can float in the plasma of blood and deposit into tissues of the body.<\/p>\n

Amyloid light-chain (AL) amyloidosis, also known as primary amyloidosis, is the most common form of systemic amyloidosis. It starts in the bone marrow, the soft tissue inside the bones that makes blood-forming cells, including cells that create antibodies to fight infections. These cells can grow abnormally, causing an excess type of protein called light chains. If someone has AL amyloidosis, the light chains clump together and form amyloid deposits in their organs. Amyloid deposits can become so severe that they cause organ failure, which is when organs stop working effectively.<\/p>\n

Treatment for AL amyloidosis is highly individualized, determined based on age, organ dysfunction, and regimen toxicities, and should be guided by biomarkers of hematologic and cardiac response. Alkylator-based chemotherapy is effective in almost two-thirds of patients. Novel agents are also active, and trials are ongoing to establish their optimal use. Some of the drugs in the pipeline include daratumumab (Janssen Pharmaceuticals), birtamimab (Prothena), CAEL-101 (AstraZeneca\/Caelum Biosciences), melflufen (Oncopeptides AB), elotuzumab (Bristol-Myers Squibb), among others.<\/p>\n

AL Amyloidosis Market Key Facts<\/strong><\/p>\n